Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 8-10 centers in the United States and Switzerland. Up to 32 patients who have undergone major cardiovascular surgery will participate. Patients will receive a single IV injection of I5NP or placebo following cardiovascular surgery. I5NP will be administered 4 hours (+/- 30 minutes) following removal of the cardiopulmonary bypass machine (CBM).

The duration of the study is approximately 44 days, inclusive of a 14 day screening period. Patients will be contacted by phone at 6 and 12 months for follow-up questions. Patient visits are screening, day of surgery, hospital in-patient Days 1, 2, 3 and Day 7 or hospital discharge. Safety follow-up will continue until 30 days post-surgery. 2 phone calls will be made at 6 and 12 months after date of surgery.


Clinical Trial Description

The drug (I5NP) is a small interfering RNA that is being developed to protect patients from acute kidney injury after cardiac bypass surgery. This first-in-man study will test the safety of I5NP and measure how long the drug stays in the blood stream after injection. This study is not meant to test if I5NP protects kidneys from the damage that may occur in rare cases during surgery. Another purpose of this dose escalation study is to find out the right dose of the experimental drug to be given to study subjects in future studies. Even though there were no harmful effects seen in the animals tested, we do not know what side effects the experimental drug might cause in humans. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00554359
Study type Interventional
Source Quark Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date August 2007
Completion date November 2010

See also
  Status Clinical Trial Phase
Completed NCT01946113 - Mineral-Homeostasis in Continuous Renal Replacement Therapy N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Withdrawn NCT00993733 - Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care N/A
Terminated NCT00978354 - Furosemide in Early Acute Kidney Injury Phase 2/Phase 3
Completed NCT00120263 - Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma N/A
Completed NCT04799600 - The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT02858531 - Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
Recruiting NCT05282732 - Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
Completed NCT01467466 - Prevention of Serious Adverse Events Following Angiography Phase 3
Completed NCT01979042 - Urinary Markers for Unilateral Kidney Obstruction N/A
Completed NCT01280617 - Low Dose Thymoglobin in Renal Transplant Patients N/A
Completed NCT00780351 - Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f) N/A
Completed NCT00971971 - Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients N/A
Completed NCT00076219 - Acute Renal Failure Trial Network (ATN) Study Phase 3
Recruiting NCT04599569 - Influence of Renal Replacement TherApy on Indirect Calorimetry
Completed NCT03727204 - Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
Completed NCT06005896 - A Clinical Model for Dialysis Discontinuation in AKI
Completed NCT03627884 - Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation Phase 4
Completed NCT03004950 - Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)